Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival BioSpaceIndirect comparisons between BridgeBio's Attruby and Pfizer's tafamidis products showed a numerical survival benefit with the biotech's drug.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug. Cardiovascular Read full story Post navigation Previous: FDA turns to old drugs to address new diseases, persistent medical needsNext: EU agrees plan to tackle essential medicine shortages Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
